Trulicity Takes Hit From Payer Mix, But Lilly Emerges From Q3 Ahead
COVID-19 Antibody Bamlanivimab Fails In Sicker Patients
US pricing for Trulicity due to payer mix fluctuations dragged down solid volume growth. Lilly hopes revenue from COVID-19 therapies will help it hit annual guidance, but bamlanivimab failed to benefit hospitalized patients.
You may also be interested in...
With disappointing revenues during Q1 due to the pandemic impact on sales and price pressure on Taltz, the pharma gave a long-term, pipeline-focused growth narrative. Alzheimer's filing plans pushed back.
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.
License deal for preclinical S-365598 continues longstanding R&D relationship between ViiV and stakeholder Shionogi, which also developed dolutegravir and cabotegravir.